Everse LA - Search Results

1

Den Otter W, Balemans L, Battermann JJ, Bernsen MR, Cadee JA, Dobrowolski Z, Everse LA, Fiszer-Maliszewska L, Gavhumende R, De Groot JW, De Groot K, Hennink WE, Hill FW, Jurgenliemp-Schulz I, Klein WR, Koten JW, Maas RA, Steerenberg P, Stewart R, Zembala M. Den Otter W, et al. Among authors: everse la. Hepatogastroenterology. 1999 May;46 Suppl 1:1280-6. Hepatogastroenterology. 1999. PMID: 10429975

2

Priming of the antitumor response promotes efficacy of interleukin-2 therapy.

Everse LA, Bernsen MR, Dullens HF, Den Otter W. Everse LA, et al. Cancer Immunol Immunother. 1997 Jun;44(4):221-9. doi: 10.1007/s002620050377. Cancer Immunol Immunother. 1997. PMID: 9222281 Free PMC article.

3

Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).

Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ. Jürgenliemk-Schulz IM, et al. Among authors: everse la. Radiat Oncol Investig. 1997;5(2):54-61. doi: 10.1002/(SICI)1520-6823(1997)5:2<54::AID-ROI3>3.0.CO;2-I. Radiat Oncol Investig. 1997. PMID: 9303058

4

Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.

Everse LA, Renes IB, Jürgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HF, Den Otter W, Battermann JJ. Everse LA, et al. Int J Cancer. 1997 Sep 17;72(6):1003-7. doi: 10.1002/(sici)1097-0215(19970917)72:6<1003::aid-ijc14>3.0.co;2-5. Int J Cancer. 1997. PMID: 9378533 Free article.

5

The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.

Everse LA, Bernsen MR, Dullens HF, Den Otter W. Everse LA, et al. J Exp Ther Oncol. 1996 Jul;1(4):231-6. J Exp Ther Oncol. 1996. PMID: 9414409

6

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.

Bernsen MR, Tang JW, Everse LA, Koten JW, Otter WD. Bernsen MR, et al. Among authors: everse la. Cancer Treat Rev. 1999 Apr;25(2):73-82. doi: 10.1053/ctrv.1998.0115. Cancer Treat Rev. 1999. PMID: 10395833 Review.

7

Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression.

Masztalerz A, Van Rooijen N, Den Otter W, Everse LA. Masztalerz A, et al. Among authors: everse la. Cancer Immunol Immunother. 2003 Apr;52(4):235-42. doi: 10.1007/s00262-003-0381-z. Epub 2003 Feb 18. Cancer Immunol Immunother. 2003. PMID: 12669248 Free PMC article.

8

Ocular squamous cell carcinoma in Simmental cattle in Zimbabwe.

Den Otter W, Hill FW, Klein WR, Everse LA, Ruitenberg EJ, Van der Ven LT, Koten JW, Steerenberg PA, Faber JA, Rutten VP. Den Otter W, et al. Among authors: everse la. Am J Vet Res. 1995 Nov;56(11):1440-4. Am J Vet Res. 1995. PMID: 8585653

9

Interleukin-2: hope in cases of cisplatin-resistant tumours.

Bernsen MR, Van Der Velden AW, Everse LA, Dullens HF, Den Otter W, Heintz AP. Bernsen MR, et al. Among authors: everse la. Cancer Immunol Immunother. 1998 Mar;46(1):41-7. doi: 10.1007/s002620050458. Cancer Immunol Immunother. 1998. PMID: 9520291 Free PMC article.

10

Analgesics in mice used in cancer research: reduction of discomfort?

van Loo PL, Everse LA, Bernsen MR, Baumans V, Hellebrekers LJ, Kruitwagen CL, den Otter W. van Loo PL, et al. Among authors: everse la. Lab Anim. 1997 Oct;31(4):318-25. doi: 10.1258/002367797780596211. Lab Anim. 1997. PMID: 9350703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page